(Q47447715)

16 January 2018

title

Covariation of amino acid positions in HIV-1 protease (English)

1 reference

https://api.crossref.org/works/10.1016/S0042-6822(03)00484-7

20 March 2024

3

Ronald Swanstrom

1 reference

16 January 2018

Noah G. Hoffman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14554082

20 March 2024

Celia A. Schiffer

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14554082

20 March 2024

language of work or name

English

0 references

publication date

1 September 2003

1 reference

16 January 2018

30 September 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14554082

20 March 2024

number of pages

13

1 reference

full work available at URL

inferred from page(s)

https://doi.org/10.1016/s0042-6822(03)00484-7

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14554082

https://api.elsevier.com/content/article/PII:S0042682203004847?httpAccept=text/xml

20 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0042-6822(03)00484-7

https://api.elsevier.com/content/article/PII:S0042682203004847?httpAccept=text/plain

20 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0042-6822(03)00484-7

20 March 2024

1 reference

16 January 2018

volume

314

1 reference

16 January 2018

issue

2

1 reference

16 January 2018

page(s)

536-548

1 reference

16 January 2018

Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Covariability of V3 loop amino acids.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Covariation of mutations in the V3 loop of human immunodeficiency virus type 1 envelope protein: an information theoretic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Associations between amino acids in the evolution of HIV type 1 protease sequences under indinavir therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precur

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

The HIV type 1 protease inhibitor saquinavir can select for multiple mutations that confer increasing resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

1 reference

7 January 2021

Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Inhibitors of HIV-1 protease: a major success of structure-assisted drug design

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900484-7

7 January 2021

Identifiers

1 reference

16 January 2018

1 reference

16 January 2018